Friday 4 October 2019
Several months ago, we engaged consultants to advise us on redeveloping 570 Elizabeth Street. After considering their expert advice, some detailed financial modelling and the likely timeframes involved, the Board has resolved that this is not feasible.
So, after more than 16 happy years in our current location, we’ll be on the move. While we would like to stay in our current precinct, if this proves not to be practicable, we’ll be sensitive about access for our members, supporters, key stakeholders and, of course, our staff. Consultants will shortly be appointed to advise us on the sale of 570 Elizabeth Street and finding our new main office. I’ll keep you updated on our progress over the next few months…
I was very pleased to be in Barcelona a few weeks ago for the 55th annual meeting of the European Association for the Study of Diabetes – one of the largest and most important annual diabetes meetings in the world. While there were no major new announcements, the latest results from a number of very important T2D clinical trials were presented. The results from the CREDENCE trial, involving an SGLT-2 inhibitor (canagliflozin), were particularly impressive in terms of the reported reductions in blood glucose levels and the improvements in key renal and cardiovascular markers – such that the trial has now been closed. Congratulations to Professor Vlado Perkovic, a Nephrologist/researcher working at the University of New South Wales and Royal North Shore Hospital in Sydney for his leadership of significant parts of this trial. Equally impressive were the latest results presented from the DECLARE trial, involving another SGLT-2 inhibitor (dapagliflozin).
On the cusp of the centenary of the first time insulin was injected into humans, the case for these SGLT-2 inhibitors (along with the GLP-1 receptor agonists) replacing insulin and metformin as first-line oral therapies for people with T2D becomes stronger, as more and more results from such clinical trials become available.
I much enjoyed the presentations at this meeting on DAFNE (structured diabetes management education for people living with T1D); on the NHS T2D prevention program; as well as the thought-provoking session on the role of psychology in our approach to the management of diabetes. It was also a pleasure to hear Professor Jane Speight present on some of the psychological issues associated with CGM use by adults with T2D in primary care.
The special issue of the EASD’s journal: Diabetologia, released in conjunction with the meeting, focused on the developmental origins of diabetes. I found this edition particularly interesting, so if you would like to follow it up, you can access it here. In addition, if you would like to read more about the abstracts and presentations at the meeting, go here.
Diabetes Australia’s Position Statement: A new language for diabetes is being updated for the first time since it was drafted by staff of the Australian Centre for Behavioural Research in Diabetes in 2011. The positive impact that this position statement has had on the language used by health professionals, the media and so forth throughout the world has been very impressive. If you would like to have your say about how this position statement might now be improved, please consider completing this survey. All going well, Diabetes Australia hopes to launch the updated position statement by the end of the year.
Finally, today is the 21st edition of Walk to Work Day, a joint initiative between Diabetes Australia and the Pedestrian Council of Australia to promote the importance of incorporating regular physical activity into our daily lives. You can donate to support Diabetes Australia’s initiatives in this area here.
With kind regards
Chief Executive Officer
We support, empower and campaign for all Victorians affected by, or at risk of, diabetes.